| RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of … DC Harrer, B Simon, S Fujii, K Shimizu, U Uslu, G Schuler, KF Gerer, ... BMC cancer 17, 1-17, 2017 | 109 | 2017 |
| The si RNA‐mediated downregulation of PD‐1 alone or simultaneously with CTLA‐4 shows enhanced in vitro CAR‐T‐cell functionality for further clinical development towards the … B Simon, DC Harrer, B Schuler‐Thurner, N Schaft, G Schuler, J Dörrie, ... Experimental dermatology 27 (7), 769-778, 2018 | 63 | 2018 |
| Cspg4 as target for CAR-T-cell therapy of various tumor entities–merits and challenges DC Harrer, J Dörrie, N Schaft International journal of molecular sciences 20 (23), 5942, 2019 | 50 | 2019 |
| Chimeric antigen receptors in different cell types: new vehicles join the race DC Harrer, J Doerrie, N Schaft Human Gene Therapy 29 (5), 547-558, 2018 | 43 | 2018 |
| Arming T cells with a gp100-specific TCR and a CSPG4-specific CAR using combined DNA-and RNA-based receptor transfer B Simon, DC Harrer, B Schuler-Thurner, G Schuler, U Uslu Cancers 11 (5), 696, 2019 | 27 | 2019 |
| Enhancing lentiviral transduction to generate melanoma-specific human T cells for cancer immunotherapy B Simon, DC Harrer, C Thirion, B Schuler-Thurner, G Schuler, U Uslu Journal of immunological methods 472, 55-64, 2019 | 24 | 2019 |
| CSPG4-specific CAR T cells for high-risk childhood B cell precursor leukemia DC Harrer, G Schuler, J Dörrie, N Schaft International journal of molecular sciences 20 (11), 2764, 2019 | 23 | 2019 |
| Biomodulatory treatment regimen, MEPED, rescues relapsed and refractory classic Hodgkin’s disease F Lüke, DC Harrer, K Menhart, D Wolff, E Holler, D Hellwig, W Herr, ... Frontiers in Pharmacology 12, 599561, 2021 | 10 | 2021 |
| RNA-transfection of g/d T cells with a chimeric antigen receptor or an a/b T-cell receptor: a safer alternative to genetically engineered a/b T cells for the immunotherapy of … DC Harrer, B Simon, SI Fujii, K Shimizu, U Uslu, G Schuler, KF Gerer, ... BMC Cancer 17, 551, 2017 | 10 | 2017 |
| Decitabine-mediated upregulation of CSPG4 in ovarian carcinoma cells enables targeting by CSPG4-specific CAR-T cells DC Harrer, C Schenkel, C Berking, W Herr, H Abken, J Dörrie, N Schaft Cancers 14 (20), 5033, 2022 | 9 | 2022 |
| Apheresis for chimeric antigen receptor T‐cell production in adult lymphoma patients DC Harrer, M Heidenreich, MA Fante, V Müller, V Haehnel, R Offner, ... Transfusion 62 (8), 1602-1611, 2022 | 9 | 2022 |
| Drug repurposing by tumor tissue editing F Lüke, DC Harrer, P Pantziarka, T Pukrop, L Ghibelli, C Gerner, ... Frontiers in Oncology 12, 900985, 2022 | 7 | 2022 |
| Continuous complete remission in two patients with acute lymphoblastic leukemia and severe fungal infection following short-term, dose-reduced chemotherapy F Lüke, DC Harrer, J Hahn, M Grube, T Pukrop, W Herr, A Reichle, ... Frontiers in Pharmacology 12, 599552, 2021 | 7 | 2021 |
| CARs and drugs: pharmacological ways of boosting CAR-T-cell therapy DC Harrer, J Dörrie, N Schaft International Journal of Molecular Sciences 24 (3), 2342, 2023 | 6 | 2023 |
| IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities DC Harrer, V Bezler, J Hartley, W Herr, H Abken Frontiers in Immunology 14, 1185618, 2023 | 4 | 2023 |
| Biomodulatory therapy induces durable remissions in multi-system Langerhans cell histiocytosis DC Harrer, M Jakob, M Vogelhuber, F Lüke, K Utpatel, S Corbacioglu, ... Leukemia & Lymphoma 63 (12), 2858-2868, 2022 | 4 | 2022 |
| Case report: extramedullary acute promyelocytic leukemia: an unusual case and mini-review of the literature DC Harrer, F Lüke, I Einspieler, K Menhart, D Hellwig, K Utpatel, W Herr, ... Frontiers in Oncology 12, 886436, 2022 | 4 | 2022 |
| Addressing genetic tumor heterogeneity, post-therapy metastatic spread, cancer repopulation, and development of acquired tumor cell resistance DC Harrer, F Lüke, T Pukrop, L Ghibelli, A Reichle, D Heudobler Cancers 16 (1), 180, 2023 | 3 | 2023 |
| Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challenges DC Harrer, SS Li, M Kaljanac, M Barden, H Pan, H Abken Frontiers in Immunology 14, 1321596, 2023 | 3 | 2023 |
| CAR triggered release of type-1 interferon limits CAR T-cell activities by an artificial negative autocrine loop DC Harrer, C Schenkel, V Bezler, M Kaljanac, J Hartley, M Barden, H Pan, ... Cells 11 (23), 3839, 2022 | 3 | 2022 |
